382 related articles for article (PubMed ID: 31295161)
1. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.
Carbone F; Van den Houte K; Clevers E; Andrews CN; Papathanasopoulos A; Holvoet L; Van Oudenhove L; Caenepeel P; Arts J; Vanuytsel T; Tack J
Am J Gastroenterol; 2019 Aug; 114(8):1265-1274. PubMed ID: 31295161
[TBL] [Abstract][Full Text] [Related]
2. Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.
Andrews CN; Woo M; Buresi M; Curley M; Gupta M; Tack J; Wilsack L; Nasser Y
Neurogastroenterol Motil; 2021 Jan; 33(1):e13958. PubMed ID: 32743954
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis.
Tack J; Rotondo A; Meulemans A; Thielemans L; Cools M
Neurogastroenterol Motil; 2016 Apr; 28(4):487-97. PubMed ID: 27010235
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.
Yiannakou Y; Piessevaux H; Bouchoucha M; Schiefke I; Filip R; Gabalec L; Dina I; Stephenson D; Kerstens R; Etherson K; Levine A
Am J Gastroenterol; 2015 May; 110(5):741-8. PubMed ID: 25869393
[TBL] [Abstract][Full Text] [Related]
5. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.
Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R
Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251
[TBL] [Abstract][Full Text] [Related]
6. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
Lembo A; Camilleri M; McCallum R; Sastre R; Breton C; Spence S; White J; Currie M; Gottesdiener K; Stoner E;
Gastroenterology; 2016 Jul; 151(1):87-96.e6. PubMed ID: 27055601
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
Camilleri M; McCallum RW; Tack J; Spence SC; Gottesdiener K; Fiedorek FT
Gastroenterology; 2017 Nov; 153(5):1240-1250.e2. PubMed ID: 28760384
[TBL] [Abstract][Full Text] [Related]
8. A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy.
Escobar-Serna DP; Peralta-Palmezano FJ; Peralta-Palmezano JJ
Arch Argent Pediatr; 2022 Apr; 120(2):e98-e101. PubMed ID: 35338825
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride.
Piessevaux H; Corazziari E; Rey E; Simren M; Wiechowska-Kozlowska A; Kerstens R; Cools M; Barrett K; Levine A
Neurogastroenterol Motil; 2015 Jun; 27(6):805-15. PubMed ID: 25808103
[TBL] [Abstract][Full Text] [Related]
10. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.
Shin A; Camilleri M; Busciglio I; Burton D; Smith SA; Vella A; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1453-1459.e4. PubMed ID: 23639598
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled trial of prucalopride for severe chronic constipation.
Camilleri M; Kerstens R; Rykx A; Vandeplassche L
N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121
[TBL] [Abstract][Full Text] [Related]
12. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects.
Kessing BF; Smout AJ; Bennink RJ; Kraaijpoel N; Oors JM; Bredenoord AJ
Neurogastroenterol Motil; 2014 Aug; 26(8):1079-86. PubMed ID: 24891067
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis.
Arts J; Holvoet L; Caenepeel P; Bisschops R; Sifrim D; Verbeke K; Janssens J; Tack J
Aliment Pharmacol Ther; 2007 Nov; 26(9):1251-8. PubMed ID: 17944739
[TBL] [Abstract][Full Text] [Related]
14. Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review.
Ali H; Pamarthy R; Sarfraz S
Cureus; 2021 Apr; 13(4):e14306. PubMed ID: 33968518
[TBL] [Abstract][Full Text] [Related]
15. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis.
Tack J; Depoortere I; Bisschops R; Verbeke K; Janssens J; Peeters T
Aliment Pharmacol Ther; 2005 Nov; 22(9):847-53. PubMed ID: 16225494
[TBL] [Abstract][Full Text] [Related]
16. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.
Talley NJ; Verlinden M; Geenen DJ; Hogan RB; Riff D; McCallum RW; Mack RJ
Gut; 2001 Sep; 49(3):395-401. PubMed ID: 11511562
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study.
Emmanuel AV; Kamm MA; Roy AJ; Kerstens R; Vandeplassche L
Aliment Pharmacol Ther; 2012 Jan; 35(1):48-55. PubMed ID: 22061077
[TBL] [Abstract][Full Text] [Related]
18. Prucalopride: a review of its use in the management of chronic constipation.
Keating GM
Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435
[TBL] [Abstract][Full Text] [Related]
19. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis.
McCallum RW; Lembo A; Esfandyari T; Bhandari BR; Ejskjaer N; Cosentino C; Helton N; Mondou E; Quinn J; Rousseau F;
Neurogastroenterol Motil; 2013 Nov; 25(11):e705-17. PubMed ID: 23848826
[TBL] [Abstract][Full Text] [Related]
20. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.
Ejskjaer N; Wo JM; Esfandyari T; Mazen Jamal M; Dimcevski G; Tarnow L; Malik RA; Hellström PM; Mondou E; Quinn J; Rousseau F; McCallum RW
Neurogastroenterol Motil; 2013 Feb; 25(2):e140-50. PubMed ID: 23279217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
